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Background: Chronic Fatigue Syndrome (CFS) is a severe, systemic illness characterized by persistent, debilitating
and medically unexplained fatigue. The etiology and pathophysiology of CFS remains obscure, and diagnosis is
formulated through the patient’s history and exclusion of other medical causes. Thereby, the availability of
biomarkers for CFS could be useful for clinical research. In the present study, we used a proteomic approach to
evaluate the global changes in the salivary profile in a couple of monozygotic twins who were discordant for CFS.
The aim was to evaluate differences of salivary protein expression in the CFS patient in respect to his healthy twin.
Methods: Saliva samples were submitted to two-dimensional electrophoresis (2DE). The gels were stained with
Sypro, and a comparison between CFS subject and the healthy one was performed by the software Progenesis
Same Spot including the Analysis of variance (ANOVA test). The proteins spot found with a ≥2-fold spot quantity
change and p<0.05 were identified by Nano-liquid chromatography electrospray ionization tandem mass
spectrometry. To validate the expression changes found with 2DE of 5 proteins (14-3-3 protein zeta/delta,
cyclophilin A, Cystatin-C, Protein S100-A7, and zinc-alpha-2-glycoprotein), we used the western blot analysis.
Moreover, proteins differentially expressed were functionally analyzed using the Ingenuity Pathways Analysis
software with the aim to determine the predominant canonical pathways and the interaction network involved.
Results: The analysis of the protein profiles allowed us to find 13 proteins with a different expression in CFS in
respect to control. Nine spots were up-regulated in CFS and 4 down-regulated. These proteins belong to different
functional classes, such as inflammatory response, immune system and metabolism. In particular, as shown by the
pathway analysis, the network built with our proteins highlights the involvement of inflammatory response in CFS
pathogenesis.
Conclusions: This study shows the presence of differentially expressed proteins in the saliva of the couple of
monozygotic twins discordant for CFS, probably related to the disease. Consequently, we believe the proteomic
approach could be useful both to define a panel of potential diagnostic biomarkers and to shed new light on the
comprehension of the pathogenetic pathways of CFS.
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Chronic Fatigue Syndrome (CFS), also termed Myalgic
Encephalomyelitis, is a severe, systemic illness character-
ized by debilitating, unexplained, persistent fatigue that
indeed has wide impact on the quality of life [1-3].
Besides the disabling fatigue, CFS is accompanied by
several symptoms that differ among patients: fatigue not
improved by rest; headaches; sleep disturbances; difficul-
ties with concentration; memory problems; muscle
weakness; musculoskeletal pain, etc. What is more is
that all these symptoms may be aggravated by physical
or mental activity [4,5]. Therefore, CFS is a medically
unexplained disorder diagnosed through symptoms
reported by the patient and the exclusion of other med-
ical and psychiatric diseases with the same symptoms.
The estimated worldwide prevalence of CFS is 0.4-2.5%,
with a peak age of onset between 20 and 40 years, and
with a female to male ratio of 3:1 [6].
This clinical disorder is considered a multi-factorial
disease with unknown etiology and pathophysiology.
Genetic studies have been performed in order to charac-
terize genes that could be useful as CFS biomarkers
[7-10]. In particular, it has been proposed that CFS is as-
sociated with immunological and inflammatory diseases
[7,8]. The over-expression of pro-inflammatory proteins,
such as interferon-γ (INF-γ), interleukin-1 (IL-1), and
tumor necrosis factor- α (TNF-α), has been reported in
CFS [9]. Besides, up-regulated immune-related genes in
patients affected by CFS such as lactotransferrin,
defensin-α1, integrins [8], CMRF35 antigen, IL-8, HD
protein [10], and cathepsin C [9] are supportive of the
notion that CFS is characterized by immune system acti-
vation. Nevertheless, at present, there are no specific
markers of inflammation and/or immune activation
which may be useful in the evaluation of patients with
CFS, thus making the treatment more complicated.
Viral infection has been usually proposed as a causa-
tive agent, but despite the efforts in the elucidation of
the role of virus, results are controversial due to a lack
of common standard clinical definition and specific bio-
markers of the disease [11-16]. Likewise, vaccines have
been depicted by some scholars as playing an important
role in CFS onset [17,18], while on the other hand,
others scholars have rejected this possibility, affirming
that the vaccine is safe [19,20].
Whilst in 2011 an International Consensus Panel de-
fined the International Consensus Criteria that identifies
the characteristic patterns of the symptom clusters of CFS
[21], the diagnosis is formulated through the patient’s
history and exclusion of other medical causes and psychia-
tric problems [5]. Thereby, the availability of biomarkers
for CFS could be of great usefulness for clinical research.
Since genetics is presumed to have a role in the etiology
of CFS, one area of investigation is the twin studies whichcould be useful in elucidating the role of genetic and
environmental factors in CFS. Nevertheless, a recent study
of Byrnes et al. [22] on monozygotic twins discordant for
CFS, did not identify a biomarker for CFS in the transcrip-
tome of peripheral blood leukocytes supposing that posi-
tive findings in prior studies may have resulted from
experimental bias. Therefore, we moved to the study of
proteins, and, for the first time, we used a proteomic
approach to evaluate in CFS the global changes of whole
saliva (WS).
Recently, the number of publications related to salivary
proteome have significantly increased suggesting human
saliva as a biological fluid with an enormous potential to
reflect systemic health conditions. Saliva has many
advantages in terms of low invasiveness, minimum cost,
and easy sample collection and processing [23]. More-
over, saliva has a less complex protein composition than
serum or plasma reducing the risk of non specific inter-
actions, and at the same time it represents a useful diag-
nostic tool since about 30% of blood proteins are also
present in saliva. Therefore, human saliva proteomics
have proven to be a novel approach in the search for
protein biomarkers for detection of diseases [23]. In
particular, in the last years, we have obtained encour-
aging results from the proteomic analysis of human WS
in rheumatic diseases [24-28]. Hence, with the present
study, we investigated the proteomics salivary profile in
a couple of monozygotic discordant for CFS. Differences
of salivary protein expression in the CFS patient in
respect to the healthy co-twin could be strictly corre-
lated to the disease itself if twins differ only regarding
the presence of CFS.
Methods
Study design
This study adopted a phase approach (Figure 1). The
first “discovery” phase was aimed at characterising the
salivary proteomic profile of a CFS subject in compari-
son to his healthy twin brother. In the second “valid-
ation” phase we performed western blot to assess the
ability of these candidate biomarkers to differentiate the
CFS from the healthy subject. Finally, we investigated
the biological function of the significantly changing
proteins, applying the Ingenuity Pathway Analysis (IPA)
Knowledge base (Ingenuity® System Inc., Redwood City,
CA, USA). This platform enabled us to visualize the
potential interactions between the identified biomarker
signatures in saliva and other molecules of interest, and
to identify biological pathways underlying the CFS
disease process.
Patients
The twins were male, non-smokers, with a body mass
index (BMI) of 22.5 (the patient) and 23.5 (the healthy
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Figure 1 Study design. This study adopted a phase approach. The first “discovery” phase characterized the salivary proteomic profile of a CFS.
The second “validation” phase assessed the differences of these candidate biomarkers in CFS in respect to healthy subject. Finally, we investigated
the biological function of the significantly changing proteins, applying the Ingenuity Pathway Analysis Knowledge base.
Table 1 Questionnaire score and scales of CFS patient
CFS Healthy twin
FIQ 61,2 4
VAS pain 3 0
VAS fatigue 8 1
VAS sleep 8 2
FACIT 26 5
SF-36
Physical functioning 50 100
Role Physical 0 100
Bodily Pain 84 100
General health status 10 67
Vitality 35 60
Social activities 25 100
Role emotional 66 100
Mental health 64 80
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are graduated, and practice the same work, in particular
they have a business company. They have the same educa-
tional background and lifestyle (both are married and have
one son). In 2005, when the twins were 31 years old, they
both received for the first time an attenuated influenza
vaccine. The twins did not have a history for autoimmune
disease or other medical conditions. Moreover, there were
not any differences in social and other stressors, not even
around the time of exposure to the flu vaccine.
Immediately after this vaccine, the patient, who was
previously healthy, developed asthenia, progressive weight
loss, forgetfulness and concentration difficulty, sleeping
disorders, dizziness and fever with indeed determined
severe work disability. Physical examination and oral
evaluation were negative in both subjects. Questionnaire
scores and scales are shown in Table 1. The twins com-
pleted an extensive questionnaire regarding demographics,
family history, CFS and other health symptoms, social
environment, and neuropsychological measures. The pa-
tients were classified based on the 1994 Centers for
Disease Control and Prevention CFS case definition [3].
Questionnaires
The twins performed a rheumatologic visit with rou-
tine clinical evaluation of medical history. The subjectscompleted the Fibromyalgia Impact Questionnaire (FIQ),
in which pain and fatigue severity were assessed with 10-
cm visual analogue score scale (VAS) and short form-36
(SF-36). Fatigue was assessed also by means of the Func-
tional Assessment of Chronic Illness Therapy-Fatigue Scale
(FACIT). We considered the VAS from the FIQ asking if
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Considerable differences were found concerning clinical
parameters, in particular fatigue and sleeping disorders.
The subjects also completed the CNS Vital Signs©, a com-
puterized neurocognitive assessment platform that enables
the objective evaluation and the characterization of the
patient’s neurocognitive function. In particular, by stan-
dardized methods, the test allows to evaluate the Compo-
site Memory, Verbal memory, Visual Memory, Processing
Speed, Executive Function, Psychomotor Speed, Reaction
Time, Complex Attention and Cognitive Flexibility. The
results of cognitive function are shown in Figure 2. The
patient resulted to have more compromised neurocog-
nitive function compared to the healthy brother.
Laboratory tests
To better classify the subjects the following haemato-
chemical parameters were evaluated:
– human leukocyte antigen (HLA) system
– immunological parameters: anti nuclear antibodies
(ANA), extractable nuclear antigen antibodies
(ENA), Rheumathoid Factor (Ra test), anti
cardiolipin antibodies (ACLA)
– hormone profile: cortisole and adrenocorticotropic
hormone (ACTH), serotonin, growth hormone
(GH), somatomedin C, progesterone, testosterone,
dehydroepiandrosterone (DHEA)
– cytokines profile: TNF-α, IL-6, IL-10, IL-2
– virological examination performed on blood and
pharyngeal swab evaluating herpes virus (HHV),
Epstein–Barr virus (EBV), Cocxsakie, parvovirus
B19, adenovirus, entero-rhinovirus, influenza and
parainfluenza virus.
HLA profile (HLA locus A03, 24; B07, 13; DRB107, 11)
















CNS Vital Signs Do
Figure 2 Results of cognitive function. (NCI) Neurocognitive index; (CM
(PrS) Processing speed; (EF) Executive function; (PsS) Psychomotor speed;negative, ANA were positive 1:160) were identical in the
subjects. A difference in haemotachemical parameters was
found concerning TNF-α (18,1 pg/ml and 2,6 pg/ml in pa-
tient and healthy twin, respectively) and IL-2 (10 pg/ml
and 46 pg/ml in patient and healthy twin, respectively).
No difference was found about IL-6, IL-10; and the hor-
mone profiles were normal (no difference was found in
twins about cortisole, ACTH, serotonin, GH, somato-
medin C, progesterone, testosterone and DHEA). Concer-
ning the virological examination, both subjects had IgG
positivity for parvovirus B19, HHV7, HHV6 and varicella
(VZV) (Table 2).Whole saliva collection
Salivary samples were collected from the patient with
CFS and from his monozygotic healthy twin brother.
Their WS was collected both in 2007 and in 2011 when
the twins were 33, and 37 years old, respectively. This
means that WS was collected after two and six years
from the flu vaccine respectively, simultaneously and at
the same interval of time. This study was approved by
the local Ethics Committee, and an informed consensus
was obtained for diagnostic or clinical purposes.
WS samples were collected early in the morning (bet-
ween 8 and 11 a.m) according to a standard protocol
[28]. The twins were asked to refrain from eating and
drinking 2 h before saliva collection. No evidence of oral
pathologies or inflammatory processes were observed.
The brothers were asked to gently chew a saliva col-
lector sponge (Surescreen Diagnostics LTD; Derby, UK)
for 2 minutes, and the saliva collected was immediately
centrifuged at 17,000 g for 20 minutes at 4°C to yield
clear samples. Samples were stored at −80°C. Protein
amounts of resulting supernatants were determined
using the Bio-Rad DC-protein assay. Bovine serum albu-




) Composite memory; (VeM) Verbal memory; (ViM) Visual memory;
(RT) Reaction time; (CA) Complex attention; (CF) Cognitive flexibility.
Table 2 Virological examination
CFS Healthy twin
IgG IgM IgG IgM
Ab anti Coxsakie 1-6 + type 4 - - -
Ab anti EBV - - - -
Ab anti HSV 1 + - - -
Ab anti HSV 2 + - - -
Ab anti HHV6 + - + -
Ab anti HHV7 + - + -
Ab anti VZV + - + -
Ab anti parvo virus B19 + - + -
Adenovirus - - - -
InfluenzaType A + - + -
Influenza Type B + - + -
Parainfluenza virus 1 and 2 - - - -
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Two hundred μg of proteins, for each sample, were filled
up to 400 μl in rehydration solution. Immobiline Dry-
Strips (GE Health Care Europe; Uppsala, Sweden); 18
cm, linear gradient pH 3–10) were rehydrated overnight
in the sample and then transferred to the Ettan IPGphor
Cup Loading Manifold (GE Healthcare) for isoelectro-
focusing (IEF). IEF was performed at 16°C and the pro-
teins were focused for up to 70000Vh. The second
dimension (Sodium Dodecyl Sulphate-Polyacrylamide
Gel Electrophoresis; SDS-PAGE) was carried out by
transferring the proteins to 12.5% polyacrylamide gel,
running at 16 mA/gel and 10°C for about 16 h. The gels
were stained with Ruthenium II tris (bathophenan-
throline disulfonate) tetrasodium salt (SunaTech Inc.;
Suzhou, P. R. China) (RuBP) as described by Aude-
Garcia et al. [29]. Briefly, after the electrophoresis, the
gels were fixed in 1% phosphoric acid (v/v) and 30%
ethanol for 1h then were stained overnight with 1 mM
RuBP in 1% phosphoric acid and 30% ethanol. After this
time the gels were destained for 5 hours in 1% phosphoric
acid and 30% ethanol and rinsed in water prior to acqui-
sition by “ImageQuant LAS4010” (GE Health Care). The
analysis of images was performed using Progenesis Same
Spot (v4.1, Nonlinear Dynamics; Newcastle Upon Tyne,
UK) software. This software generates 2DE analyses which
are robust and accurate. Briefly, the gels were aligned to
place all spots in exactly the same location, and after-
wards, the spot detection produced a complete data set
since all gels contain the same number of spots, each
matched to its corresponding spot on all gels. After 2DE
gel alignment and subsequent spot detection, the software
calculated background corrected abundance, by determin-
ing the lowest intensity value of the image pixels outsidethe spot’s outlined, and subtracting it from the intensity
value of every pixel inside the spot outline. Theses
abundances were then normalized compared to a
reference gel in order to obtain a normalized intensity
value for each spot.
The 2DE experiments were performed in triplicate.
The spot volume ratios between the two different condi-
tions were calculated using the average spot normalized
volume of the three biological replicates (http://www.
nonlinear.com/). The software included statistical ana-
lysis calculations.
2DE statistical analysis
A comparison between CFS and healthy subject was
performed. The significance of the differences of nor-
malized volume for each spot was calculated by the
software Progenesis Same Spot including the Analysis of
variance (ANOVA test). The protein spots with a ≥2-fold
spot quantity change and p<0.05 were cut out from the
gel and identified by Nano-liquid chromatography elec-
trospray ionization tandem mass spectrometry (NanoLC-
ESI-MS/MS) analysis.
NanoLC-ESI-MS/MS Analysis by LTQ-Orbitrap Velos analysis
The gel pieces were destained in 100% ethanol during
2 hours. Subsequently, they were rehydrated with 100 μl
of 50 mM ammonium bicarbonate for 15 min and dehy-
drated with 100 μl of 50 mM ammonium bicarbonate in
30% acetonitrile (AcN) for 15 min.
The gel pieces were then dried for 30 minutes in a
Centrivap vacuum centrifuge (Labconco, Kansas City,
USA). The dried pieces of gel were rehydrated for 45 min
at 4°C in 20 μl of trypsin porcine (Sigma-Aldrich; MO,
USA) solution (6.25 ng/μl in 50 mM ammonium bicar-
bonate) and then incubated at 37°C overnight. Extraction
of the peptides was performed with 20 μl of 1% trifluo-
roacetic acid (TFA) for 30 min at room temperature with
occasional shaking. The TFA solution containing the pro-
teins was transferred to a polypropylene tube. A second
extraction of the peptides was performed with 20 μl of
0.1% TFA in 50% AcN for 30 min at room temperature
with occasional shaking. The second TFA solution was
pooled with the first one. The volume of the pooled
extracts were dried completely and finally resuspended in
AcN/formic acid 50%/0.1%.
LC-ESI-MS/MS was performed on a linear trap quad-
rupole (LTQ) Orbitrap Velos from Thermo Electron
(San Jose, CA, USA) equipped with a NanoAcquity
system from Waters. Peptides were trapped on a home-
made 5 μm 200 Å Magic C18 AQ (Michrom) 0.1 ×
20 mm pre-column and separated on a home-made 5 μm
100 Å Magic C18 AQ (Michrom) 0.75 × 150 mm column
with a gravity-pulled emitter. The analytical separation
was run for 23 min using a gradient of H2O/formic acid
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(solvent B). The gradient was run as follows: 0–5 min 95%
A and 5% B, then to 65% A and 35% B at 6 min, and 20%
A and 80% B at 7 min at a flow rate of 220 nL/min. For
MS survey scans, the orbitrap (OT) resolution was set to
60000 and the ion population was set to 5 × 105 with an
m/z window from 400 to 2000. For protein identification,
up to five precursor ions were selected for collision-
induced dissociation (CID). For MS/MS in the LTQ, the
ion population was set to 1 × 10e4 (isolation width of
2 m/z), while as for MS/MS detection in the OT, it
was set to 1 × 10e5 (isolation width of 2 m/z). The norma-
lized collision energies were set to 35% for CID.Protein identification
Peak lists were generated from raw orbitrap data using
the embedded software from the instrument vendor
(extract_MSN.exe). The monoisotopic masses of the se-
lected precursor ions were corrected using an in-house
written Perl script [30]. The peaklist files were searched
against the UniProtKB/Swiss-Prot database (Release-
2011_08 of 21-Sep-2011) using Mascot (Matrix Sciences,
London, UK). Human taxonomy (20323 sequences) was
specified for database searching. The parent ion toler-
ance was set to 10 ppm. Variable amino acid modifica-
tions were oxidized methionine and fixed amino acid
modifications were carbamidomethyl cysteins. Trypsin
was selected as the enzyme, with one potential missed
cleavage, and the normal cleavage mode was used. The
mascot search was validated using Scaffold 3.6.0 (Prote-
ome Software, Portland, OR). Only proteins matching
with two different peptides with a minimum probability
score of 95% were considered identified.Western blot analysis
To validate the expression changes found with 2DE, we
used western blot analysis. Mono-dimensional western
blot was performed as previously described [31] for 14-
3-3 protein zeta/delta, cyclophilin A (CYPA), Cystatin-C,
and Protein S100-A7. Briefly, aliquots of WS samples
were run on 12% SDS-PAGE gels (14-3-3 protein zeta/
delta, CYPA, Cystatin-C) or on 15% SDS-PAGE gels
(Protein S100-A7). The amount of proteins loaded and
the dilution of primary antibody was different depending
on each protein analysed (14-3-3 protein zeta/delta and
CYPA: 50 μg of proteins and dilution of 1:500, Cystatin-
C 20 μg and a dilution of 1:200, Protein S100-A7 40 μg
and 1:200). The immunocomplexes were detected
using a peroxidase-labelled secondary antibody (goat
anti-rabbit, 1:10000 dilution; goat anti-mouse, 1:20000;
donkey anti-goat, 1:5000). Immunoblots were developed
using the ECL detection system. The chemiluminescent
images were acquired by LAS4010 (GE Health Care).To visualize the different expression of zinc-alpha-2-
glycoprotein (ZAG), aliquots of WS corresponding to
300 μg of proteins, were separated by 2DE using 3–10
linear strips (18 cm) and 12,5% gels before western blot
analysis with specific antibody (1:1000 dilution).
Western blot statistical analysis
The antigen-specific bands were quantified using the
Image Quant-L (GE Health Care) software. Data were
reported as optical density and subjected to statistical
analysis with Student t-test making a comparison of
protein expression levels between CFS and control.
Signaling pathway analysis
Proteins differentially expressed, were functionally ana-
lyzed using the Ingenuity Pathways Analysis (IPA)
software v14400082 (2012 Ingenuity Systems, Inc. www.
ingenuity.com) with the aim to determine the predo-
minant canonical pathways and interaction network
involved. Swiss-Prot accession numbers and official gene
symbols were inserted into the software along with cor-
responding comparison ratios between the CFS patient
and the healthy brother. The network proteins asso-
ciated with biological functions and/or diseases in the
Ingenuity Pathways Knowledge Base were considered for
the analysis. These networks are scored for degree of
relevance with values >3 having a 99.9% confidence level
of not being generated by random chance alone. The
created genetic networks describe functional relation-
ships among proteins based on known associations in
the literature.
Results
Proteomic analysis and validation by western blot
Figure 3 illustrates the salivary profiles of the healthy
twin brother (A) and of the patient (B). Overall, we
found 13 spots differently expressed in CFS in respect to
the control with a fold variation ≥ 2. Nine spots were up-
regulated in CFS and 4 down-regulated. A list of identified
proteins, with molecular weight (MW), isoelectric point
(pI), coverage and score values of NanoLC-ESI-MS/MS is
given in Table 3. Table 4 shows the statistical analysis: the
normalized volume (mean ± SD) of each spot with
p-value and fold-change in expression levels between
samples.
Western blot analysis with specific antibodies was used
to validate the expression changes of four proteins: 14-3-3
protein zeta/delta (n°1051), CYPA (n°1509), Cystatin-C
(n°1575), and Protein S100-A7 (n°1621) (Figure 4A, 4B).
The immunoblot for each protein tested is shown in
Figure 4 panel C. For each protein the optical density of
specific immunoreactive band was determined and the
resulting values compared (Figure 4D). With 2DE we


























Figure 3 2DE patterns of human saliva. 2DE patterns of human WS: healthy subject (A) and patient with CFS (B). A total of 200 μg of proteins was
separated by 2DE using 18 cm pH 3-10L strips and 12.5% SDS-PAGE. The 13 spots differently expressed in CFS in respect to control are indicated.
Table 3 MS/MS data of salivary proteins found differentially expressed between CFS patient and his healthy twin









P01833 PIGR 80 83 5.6 5.6 7 12% 82.8 (R)QSSGENcDVVVNTLGKR(A)
815 Ig alpha-1 chain C region P01876 IGHA1 38 38 6.2 6.1 2 7% 60.9 (K)TFTcTAAYPESK(T)
1509 Cyclophilin A P62937 PPIA 18 18 7.5 7.7 6 46% 63.1 (K)KITIADcGQLE(−)
Inflammatory response
1575 Cystatin-C P01034 CST3 16 16 9.3 9 3 25% 49.7 (R)ALDFAVGEYNK(A)
1620 Cystatin-B P04080 CSTB 14 11 6.6 7 4 70% 51.3 (K)VHVGDEDFVHLR(V)




P52209 PGD 48 53 6.7 6.8 2 6% 69.2 (K)GILFVGSGVSGGEEGAR(Y)
1736 Zinc-alpha-2-glycoprotein P25311 AZGP1 36 34 5.5 5.7 8 27% 67.5 (R)AKAYLEEEcPATLR(K)
1736A Zinc-alpha-2-glycoprotein P25311 AZGP1 36 34 5.5 5.7 2 5% 94.3 (R)AKAYLEEEcPATLR(K)
Signal transduction
528 Rab GDP dissociation
inhibitor beta
P50395 GDI2 50 51 5.9 6.1 3 9% 50.9 (R)mTGSEFDFEEmKR(K)
1038 14-3-3 protein sigma P31947 SFN 33 28 4.6 4.7 8 38% 84.7 (K)SNEEGSEEKGPEVR(E)
1051 14-3-3 protein zeta/delta P63104 YWHAZ 33 28 4.8 4.7 3 20% 45.5 (K)LAEQAERYDDmAAcmK(S)
Others
452 Serum albumin P02768 ALB 57 69 6.2 5.9 8 14% 84.5 (K)VPQVSTPTLVEVSR(N)
501 Alpha-amylase 1 P04745 AMY1A 52 58 6.5 6.5 5 11% 98.3 (K)TGSGDIENYNDATQVR(D)
(obs: observed; th: theoretical).
ID: SwissProt accession number of the protein; Gene name: name of the corresponding gene; Matched peptides: the number of unique peptides on which the
protein identification is based; Coverage: the percentage of the protein's sequence represented by the peptides identified by MS; Best ion score: it is a measure of
how well the observed MS/MS spectrum matches to the stated peptide; Peptide identified: each spot corresponding to one certain protein had at least one of the
shown peptides identified.
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Table 4 Results of 2DE statistical analysis
n° spot Protein name ctrl ± SD CFS ± SD Fold CFS p-value
91 Polymeric immunoglobulin receptor 2.35e+06 ± 3.31e+05 1.09e+06 ± 1.67e+05 - 2.2 0.003
452 Serum albumin 1.72e+05 ± 1.64e+04 7.78e+05 ± 9.87e+04 + 4.5 0.0001
501 Alpha-amylase 1 1.13e+05 ± 3.15e+04 5.31e+05 ± 6.59e+04 + 4.7 0.0009
528 Rab GDP dissociation inhibitor beta 1.27e+05 ± 2.27e+04 .88e+05 ± 6.66e+04 + 3.1 0.001
545 6-phosphogluconate dehydrogenase. decarboxylating 5.18e+05 ± 7.04e+04 1.32e+06 ± 3.09e+04 + 2.5 0.01
815 Ig alpha-1 chain C region 5.36e+05 ± 7.90e+04 8.61e+04 ± 1.90e+04 - 6.2 0.0003
1038 14-3-3 protein sigma 5.08e+05 ± 7.43e+04 1.73e+06 ± 1.12e+05 + 3.4 0.0002
1051 14-3-3 protein zeta/delta 1.19e+05 ± 3.01e+04 5.80e+05 ± 9.25e+04 + 4.9 0.0009
1509 Cyclophilin A 2.64e+05 ± 5.54e+04 7.00e+05 ± 7.87e+04 + 2.6 0.02
1575 Cystatin-C 2.47e+06 ± 1.13e+06 2.55e+05 ± 4.38e+04 - 9.7 0.001
1620 Cystatin-B 3.08e+06 ± 3.47e+05 8.77e+06 ± 4.04e+05 + 2.8 0.01
1621 Protein S100-A7 1.46e+05 ± 2.34e+04 5.80e+05 ± 2.25e+05 + 4.0 0.004
1736/A Zinc-alpha-2-glycoprotein 2.37e+06 ± 8.06e+03 9.61e+05 ± 8.30e+04 - 2.5 0.008
The normalized volume (mean±SD) of each spot with p-value and fold-change in expression levels in whole saliva of CFS in respect to control.
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0.0009, 0.02, 0.004 respectively (Figure 4B) that was con-
firmed with western blot. Also the decrease of Cystatin-C
(p-value=0.001) was confirmed by western blot analysis.
These experiments of validation were carried out on WS
collected both in 2007 and in 2011, when the twins were
33 and 37, and in both case the results supported those of
the 2DE study.
Moreover, we conducted mono-dimensional western
blot analysis also for ZAG, but the lower value in the
twin with CFS was not significant with a fold variation
of 2.0 and 1.2 in WS collected in 2007 and 2011 respec-
tively (Figure 5 panel B). Actually, by 2DE we found two
close spots corresponding to ZAG (n°1736, n°1736A)
(Figure 5 panel A, and Table 3), and the mono-dimen-
sional electrophoresis could not allow us to appreciate the
real difference of this protein in WS. Therefore, we
performed 2DE immunoblotting to evaluate the dif-
ferences of expression observed in different spots. The
detected immunoreactive spots were four and they
corresponded to pI values ranging from 5.4 (spot 1) to 5.9
(spot 4) (Figure 5 panel C). The significant decrease in
CFS in respect to control was observed for all spots
detected by 2DE immunoblotting confirming the result
obtained by 2DE and NanoLC-ESI-MS/MS.
Potential Biomarkers found in CFS
Table 5 summarizes the potential biomarkers found in
CFS with their functional properties. Moreover, we
performed a preliminary validation on a larger number
of patients for one of these proteins: CYPA (data not
shown). ELISA assay for CYPA was carried out on WS
of 20 patients affected by CFS, and 20 healthy subjects,
confirming the up-regulation of this protein: the p-valuewas 0.03, and the fold variation of this protein in CFS
respect to controls was 2.4.
Pathway and network analysis
The 13 proteins that distinguish the WS of the CFS
patient from the healthy subject were used for bioinfor-
matic analysis to identify biological function and path-
ways involved in CFS using IPA. IPA software allows to
investigate the relationship between those proteins and
various biological pathways. Figure 6 shows the pre-
dominant canonical pathways generated by uploading
proteins in Table 4. The software generated different
networks. The one with the highest score (score value 21)
encompassed 35 proteins and was associated with “Cellu-
lar movement, Hematological System Development and
Function, Immune Cell Trafficking”. Eight of these
proteins were found in our analysis. The top function
linked with these biomarkers was the inflammatory res-
ponse (p-value 3.78E-05-4.99E-02) that is associated with 8
of our proteins.
Discussion
This work, for the first time, used a proteomic approach
to evaluate the global changes in WS in a patient with
CFS. In our large cohort of patients with CFS, we
selected a patient with a monozygotic twin brother; des-
pite the two subjects had the same genetic, education,
lifestyle and practiced the same work, one of them
developed CFS after a vaccine. Despite this pilot study
analysed only two subjects, the differences of salivary
protein expression could be linked to the disease itself,
since the twins differed only regarding the presence of
CFS. By this way, our study on a couple of twins could



























































































































Figure 4 Proteins differentially expressed in CFS saliva. Enlarged images of 4 proteins found up- or down-regulated in WS of CFS patient
in respect to control subject (A), and histograms of the normalized volume (M±SD) obtained with 2DE analysis for these proteins (B). Western
blot analysis of these 4 proteins in WS collected both in 2007 and in 2011 (C), and the respective histograms of the optical density (OD).
Each bar represents the mean±SD (D). As depicted in Figure 4D, the modulation illustrated in Figure 4B has been confirmed. (* p< 0.05,
** p< 0.01, *** p< 0.001).
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wide number of patients, in order to confirm their use-
fulness in the diagnosis and therapy of CFS. At present,
few proteomics works on CFS have been carried out on
cerebrospinal fluid [32,33], and on serum [34] while in
our study we decided to explore the WS of CFS patient
preferring to adopt a less invasive procedure in collec-
ting the samples. Although WS is a less complex fluid, it
has been proved to be a promising diagnostic tool
[23-28], and we found an alteration of protein patterns
in the patient in respect to his control.
Immune system
Concerning the proteomic analysis on WS, our results
showed an increase of CYPA with a fold of 2.6, whichwas also confirmed by the western blot analysis and veri-
fied in WS collected in different years. CYPA was pre-
viously found up-regulated in WS of patients affected by
Sjögren’s syndrome and Systemic sclerosis [28,35] sus-
taining the role of CYPA in the pathogenesis of
immune-mediated disorders [36]. Moreover, viral infec-
tions have been discovered to promote the secretion of
CYPA [37-39] supporting the hypothesis that a persist-
ent viral infection may contribute to the pathogenesis of
CFS [11].
Besides, the decrease of Ig alpha-1 chain C and of
polymeric immunoglobulin receptor (pIgR) that we ob-
served could have promoted the viral infection/immuno-
logical alteration. In fact, Ig alpha-1 chain C has a role
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Figure 5 Expression of ZAG. Enlarged image of ZAG in 2DE gel with the histogram of the normalized volume (M±SD) (A), and validation of
ZAG with mono-dimensional western blot (B), and 2DE western blot (C). With 2DE immunoblotting we found 4 spots corresponding to ZAG
(spot 1- spot 4) with pI values ranging from 5.4 (spot 1) to 5.9 (spot 4). The decrease in CFS in respect to control was observed for all spots
detected by immunoblotting. (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not significant).
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the mucosa against incoming pathogens [40] and it is re-
sponsible for intracellular neutralization of some viruses
through its secretory component [41]. For example,
Takiguchi and colleagues observed a reduction in pIgR
in dextran sodium sulfate-induced colitis (DSS) [42]
supporting the preventive role of pIgR proposed by
Murthy et al. [43]. DSS is a model that has been widely
used to investigate the mechanisms of inflammatory
bowel diseases, which are chronic inflammatory dis-
orders [42]. The mucosal immune system is primarily
responsible for preventing infection caused by luminal
microorganisms by inhibiting bacterial attachment or
invasion, and it has been proposed that pIgR may be
necessary for maintaining the basal tone of innate im-
munity in the intestinal environment [42,43]. Therefore,
these studies support the involvement of pIgR in the
protection against environmental antigens [42,43].
Furthermore, the altered regulation of the immune
system in CFS patients is one of the area of interest in
the research of biomarkers for CFS. Brenu and col-
leagues found immunological abnormalities, in particular
a reduced cytotoxic activity of innate immune cells,
which they proposed as a potential diagnostic tool for
CFS [44,45].In this direction the increase of Human S100A7
(psoriasin) that is overexpressed in inflammatory diseases
could be also seen.
Inflammatory response
Psoriasin has been associated with increased inflam-
matory cell infiltrates in breast cancer and various
inflammatory disorders [46-49]. As shown by the path-
way analysis, the network built with our proteins high-
lights the involvement of inflammatory response in CFS
pathogenesis.
Among the proteins changed in CFS in respect to the
healthy subject, we found two proteins which belong to
the cysteine proteinase inhibitors family: cystatin C and
B. Cystatins function as tight-binding inhibitors of
cathepsins, which are cysteine proteinases involved in a
number of important cellular processes including in-
flammation [50]. A broad spectrum of biological roles
have been suggested for cystatins, including a role in
protein catabolism, in the regulation of hormone pro-
cessing and bone resorption, in inflammation, in antigen
presentation and T-cell dependent immune response as
well as resistance to various bacterial and viral infections
[50]. Salivary cystatins are likely to exert certain antiviral
effect as they can interfere with events in viral replication
Table 5 Functional properties of salivary proteins found differentially expressed between CFS patient and his healthy
twin
n° Protein name Functional properties
Immune system
1509 cyclophilin A Protein with peptidyl-prolyl cis-trans isomerase activity, which accelerates the folding of proteins
and catalyzes conformational changes in several cellular processes.
815 Ig alpha-1 chain C region Ig alpha is the major immunoglobulin class in body secretions. It may serve both to defend against
local infection and to prevent access of foreign antigens to the general immunologic system.
91 Polymeric immunoglobulin
receptor
This receptor binds polymeric IgA and IgM at the basolateral surface of epithelial cells.
The complex is then transported across the cell to be secreted at the apical surface. During
this process a cleavage occurs that separates the extracellular (known as the secretory component)
from the transmembrane segment
Inflammatory response
1621 Protein S100-A7 It has been associated with increased inflammatory cell infiltrates in breast cancer and various
inflammatory disorders, and recently its role in the production of pro-inflammatory molecules
has been demonstrated on breast tumor cells.
1575 Cystatin-C Proteins with a role in protein catabolism, in regulation of hormone processing and bone resorption,
in inflammation, in antigen presentation and T-cell dependent immune response as well as resistance
to various bacterial and viral infections.
1620 Cystatin-B Cystatin-B is an intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of
cathepsins L, H and B.
Signal transduction
1051 14-3-3 protein zeta/delta Phosphoserine/phosphothreonine-recognition proteins implicated in the regulation of many intracellular
signaling. 14-3-3 proteins form homo- or hetero dimers and they can bind different molecules (e.g. kinases,
phosphatases, transmembrane receptors and transcription factors).
Metabolism
1736 Zinc-alpha-2-glycoprotein (ZAG) It is mainly known as an adipokine responsible for lipid degradation that causes loss of adipose tissue
in cancer cachexia. Beyond this action, a role of ZAG in the activation of AMP kinase, an important regulator
of energy metabolism, in human skeletalmuscle cells has emerged.
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B, and a down-regulation of cystatin C. These two cysta-
tins belong to two different subtypes of cystatin, type I
and II respectively. It was demonstrated that they have
different functions, e.g., type I cystatins are up-regulated
in tumor tissue while type II cystatins are generally down-
regulated in tumors [50]. Therefore, we believe our find-
ings could suggest that the balance between cysteine
proteinases and their inhibitors is impaired in CFS.
Signal transduction
In the WS of our CFS patient, we detected the signifi-
cant increase of two members of 14-3-3 family in respect
to his healthy brother. This family is a class of phos-
phoserine/phosphothreonine (pSer/Thr)-recognition pro-
teins implicated in the regulation of many intracellular
signaling [53]. Many organisms express multiple isoforms,
and we found isoforms sigma and zeta/delta. Therefore,
14-3-3 proteins are involved in a wide range of pa-
thological processes [53] and by means, the increase is
probably not CFS-specific. For example, we previously
found an up-regulation of 14-3-3 proteins also in rheu-
matoid arthritis [26]. In addition, Matsuo et al. have re-
cently found 14-3-3 protein level increased in a patient
with Sjögren’s syndrome, but the patient was originallysuspected to suffer from Creutzfeldt-Jakob disease (CJD)
[54] since 14-3-3 protein was considered an important
diagnostic marker of CJD [55]. So they supported the
assumption that 14-3-3 is non-specifically increased in
various diseases.
Metabolism
Finally, we observed a down-regulation in CFS of ZAG.
We found two spots in 2DE gels corresponding to this
protein and, since the specific antibody has a greater
sensitivity in respect to any staining protocol, with west-
ern blot we found two other spots, all confirming the
decrease. ZAG is mainly known as an adipokine respon-
sible for lipid degradation that causes loss of adipose
tissue in cancer cachexia. However, beyond this action, a
role of ZAG in the activation of AMP kinase (AMPK),
an important regulator of energy metabolism, in human
skeletalmuscle cells has emerged [56]. The mechanism
may be involved in mediating the effects of ZAG in rela-
tion to increased energy utilization. This is interesting if
we consider that several studies suggest an organic cause
for CFS related to defects in oxidative metabolism. In
particular, individuals with CFS reach exhaustion (in the
presence of reduced sarcoplasmic ATP concentrations)
much more rapidly in respect to healthy subjects with
Figure 6 Network analysis of differentially expressed proteins. The canonical pathway of differentially expressed proteins with the highest
score, obtained by using IPA. Proteins increased in CFS are colored in red and those that decrease in abundance relative to healthy control are
colored in green.
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muscles [57]. Moreover, one of the primary symptoms of
CFS is muscle pain and weakness; this process is
probably the result of cellular changes [57] such as re-
duction in the number of motor units and atrophy due
to disuse. Considering that Russell and colleagues have
demonstrated the ability of ZAG to reduce reactive
oxygen species (ROS) production and to counter muscle
atrophy associated with insulin resistance and other
catabolic conditions [58], the decrease of ZAG that we
found in WS seems to support the hypothetical role of oxi-
dative stress in CFS. From the same point of view we can
explain the increase of 6-phosphogluconate dehydrogenasein WS of CFS. This is an enzyme of the oxidoreductase
class that allows the production of NADPH which is
necessary for protection against ROS.
Conclusions
In conclusion, this study on a couple of monozygotic
twins discordant for CFS point out some proteins which
are useful both to define a panel of potential diagnostic
biomarkers and to shed new light on the comprehension
of the pathogenetic pathways of CFS. There is a clear
need to extend our results on a larger number of sub-
jects with similar medical history, and our preliminary
results are encouraging for our future study.
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